Insider Buying: BioCardia (NASDAQ:BCDA) Director Acquires $39,000.00 in Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 39,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was bought at an average price of $1.00 per share, with a total value of $39,000.00. Following the completion of the acquisition, the director directly owned 166,338 shares in the company, valued at approximately $166,338. This represents a 30.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

BioCardia Trading Up 10.1%

NASDAQ:BCDA opened at $1.20 on Friday. The company has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.17. The stock has a market cap of $13.65 million, a price-to-earnings ratio of -1.32 and a beta of 0.51. BioCardia, Inc. has a 12 month low of $0.78 and a 12 month high of $2.45.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Equities analysts forecast that BioCardia, Inc. will post -0.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BCDA shares. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of BioCardia in a report on Tuesday, June 9th. Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $25.00.

Institutional Trading of BioCardia

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cetera Investment Advisers bought a new position in shares of BioCardia in the 2nd quarter worth about $40,000. DRW Securities LLC bought a new stake in BioCardia during the fourth quarter worth about $72,000. Finally, Geode Capital Management LLC boosted its stake in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares in the last quarter. 20.57% of the stock is owned by hedge funds and other institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.